Browse News
Filter News
Found 485,471 articles
-
Warp Drive Bio inked a strategic collaboration deal with Roche for up to $387M.
-
Incyte Claims Flexus Lured Away CSO and Its IDO Secrets, Then Sold Itself to Bristol-Myers in $1....
10/16/2017
Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research. -
Cabometyx hit key endpoints of overall survival in its Phase III liver cancer trial and investors are overjoyed.
-
The approval has made Flexion an even bigger target of acquisition rumors.
-
Ionis Pharma released new data from its Phase III NEURO-TTR trial with inotersen in patients with hereditary TTR amyloidosis with polyneuropathy.
-
In a filing with the SEC,Orexigen indicated that it may not have enough funds to continue operating.
-
The new venture capital fund with a focus on early-stage companies is making waves in the biotech world.
-
Strong, durable responses seen against lung tumors and brain metastases across multiple lines of therapy.
-
Ramaswamy's Myovant Sciences Scores $140M
10/16/2017
Myovant Sciences has secured up to $140 million in flexible financing commitments from NovaQuest Capital Management and Hercules Capital. -
The Parker Institute for Cancer Immunotherapy today announced that researchers at Dana-Farber Cancer Institute have joined its network.
-
Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income.
-
Follow-up meeting with the FDA is expected before year end.
-
Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
10/16/2017
The study was published in Clinical Cancer Research, a high impact, peer-reviewed medical journal.
-
Fennec Announces Positive Results From Phase III SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology 2017 Meeting
10/16/2017
The SIOPEL 6 study met its primary endpoint.
-
Zogenix's Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy
10/16/2017
Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C.
-
Cara Therapeutics Announces Successful End-of-Phase II Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
10/16/2017
Cara, in consultation with the FDA, has established the key elements of the Phase 3 program to support a New Drug Application (NDA) for I.V. CR845.
-
New clearance for the TLL system includes indications for use with allogeneic bone graft and in additional levels of the spine.
-
Flex Pharma Initiates CMT Phase II Trial With FLX-787 in U.S.
10/16/2017
ALS Phase 2 Trial Currently Underway
-
TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
10/16/2017
TG announced that clinical abstracts featuring data from the Phase II multicenter trial of TG-1101 have been selected for presentation at an upcoming conference.
-
Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase I Study of Autologous ATA190 in Patients with Progressive MS
10/16/2017
Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements.